Boardroom Alpha
Boardroom Alpha
AFCG · Current Report (Form 8-K) · Filed January 29, 2026

Advanced Flower Capital Inc — Current Report (Form 8-K)

Form
8-K
Filed
January 29, 2026
Period
Jan 27, 2026
Ticker
AFCG
Accession
0001829126-26-000724
Boardroom Alpha · Filing insights

Advanced Flower Capital obtains a $20M unsecured revolver with a related-party lender for general corporate purposes.

About Advanced Flower Capital Inc
Market cap
$88M
1Y TSR
−27.8%
3Y TSR
−18.7%
Board grade
C-
Sector
Real Estate
CEO
Daniel Neville
Last annual meeting: May 28, 2026 · View full Advanced Flower Capital Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 27, 2026

 

ADVANCED FLOWER CAPITAL INC.

(Exact name of registrant specified in its charter)

 

Maryland   001-39995   85-1807125
(State or Other Jurisdiction
Of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

477 S. Rosemary Ave., Suite 301

West Palm Beach, FL, 33401

(Address of principal executive offices, zip code)

 

Registrant’s telephone number, including area code: (561) 510-2390

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock, par value $0.01 per share   AFCG   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On January 27, 2026, Advanced Flower Capital Inc., a Maryland corporation (the “Company”), entered into an unsecured revolving credit agreement (the “Credit Agreement”) with TCGSL LLC, acting as agent and lender (in such capacity, the “Lender”). TCGSL LLC is indirectly wholly-owned by Leonard M. Tannenbaum, Chairman of the Company’s Board of Directors, and certain members of his immediate family and certain trusts for their benefit, and an affiliate of the Company within the meaning of that term as set forth in the Investment Company Act of 1940, as amended. The Credit Agreement provides for an aggregate commitment by the Lender of $20,000,000 and matures on August 1, 2028. Capital drawn by the Company pursuant to the Credit Agreement may be used for general corporate purposes, including portfolio investments.

 

The foregoing description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement, which is filed with this report as Exhibit 10.12 and incorporated herein by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant

 

The information provided in Item 1.01 of this Current Report relating to the Credit Agreement is incorporated by reference into this Item 2.03.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are being filed with this Current Report.

 

Exhibit   Description
10.12   Unsecured Revolving Credit Agreement, dated as of January 27, 2026, by and between the Company, as borrower, and TCGSL LLC, as lender and agent thereto.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ADVANCED FLOWER CAPITAL INC.
         
Dated: January 28, 2026   By: /s/ Brandon Hetzel
       

Brandon Hetzel

Chief Financial Officer and Treasurer

 

2

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Advanced Flower Capital Inc (AFCG)

Reference

Frequently asked questions

When did Advanced Flower Capital Inc file this 8-K?
Advanced Flower Capital Inc (AFCG) filed this Current Report (Form 8-K) with the SEC on January 29, 2026. The accession number assigned by EDGAR is 0001829126-26-000724.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Advanced Flower Capital obtains a $20M unsecured revolver with a related-party lender for general corporate purposes. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Advanced Flower Capital Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Advanced Flower Capital Inc has filed under CIK 1822523, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer